Predict your next investment

Corporation
lesaffre.com

See what CB Insights has to offer

Investments

1

Portfolio Exits

1

Partners & Customers

1

About Lesaffre

Lesaffre markets yeast, ingredients, sourdoughs, and yeast extracts for the baking, healthcare, and biotechnology industries.

Lesaffre Headquarter Location

137 rue Gabriel Peri

Marcq-en-Baroeul, 59700,

France

+33 (0)3 20 81 61 00

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Lesaffre News

Industrial Enzymes Market Size to Surpass US$ 9.7 Bn by 2030

Dec 3, 2021

Companies Covered BASF SE; Adisseo; Novozymes; DuPont Danisco; DSM; Novus International; Associated British Foods plc; Lesaffre; Chr. Hansen Holding A/S; Advanced Enzyme Technologies; Enzyme Development Corporation Regional Snapshots North America dominated the Industrial Enzymes Market in 2020 contributing a market share of more than 35% and is estimated to grow significantly over the forecast period owing to the major market players in the region and the continuous research and developmental activities carried by these market players in order to find innovative applications of the industrial enzymes. For instance, On 6th October 2021, CHOOZIT FIT, a culture series for pasta filata cheese makers in Brazil, has been announced by IFF. Unlike other products on the market, CHOOZIT FIT is a phage-resistant culture series that enables medium-sized cheese manufacturers to produce high-quality, stretchy mozzarella that is exceptionally durable and consistent. Market Dynamics Driver The high adoption of enzymes in the food industry for making various dairy products, the rising demand for digestive and nutritional enzymes, the increase in usage due to numerous environmentally friendly industrial activities, the increase in product usage in detergent manufacturing. Restraint In the projected period, the industrial enzymes market will be hampered by the rigorous regulatory framework and limitations identified in the use of enzymes, such as poor thermal stability and limiting substrate scope. Opportunity The rising need for an alternative to synthetic chemicals, combined with technological advancements and a broad industry scope, are providing several new chances for the industrial enzymes market to develop during the forecast period. Challenges The use of enzymes has some drawbacks, such as low thermal stability and a small substrate range and this is expected to be a major challenge that is encountered by the Industrial Enzymes Market. Report Highlights The Carbohydrates product segment is expected to lead the market contributing more than 47.5% of the revenue share in the upcoming years. The Microorganisms source segment leads the market with a market share of more than 80.5% in 2020 and is estimated to grow significantly in the forecast period. The Food & Beverages Application segment of the Industrial Enzymes Market leads the market with a market share of more than 22% in 2020 and is estimated to grow significantly in the forecast period. By Geography, North America holds a significant share accounting for more than 35% revenue share in 2020 in the Industrial Enzymes Market because of the presence major market players in the region. Browse more related reports@ https://www.precedenceresearch.com/industry/chemical-and-material Recent Developments In January 2021, Advanced Enzyme Technologies acquired a 51 percent controlling stake in SciTech Specialties Private Limited (SSPL) by subscribing to the issue of 492,630 SSPL equity shares and purchasing 27,778 SSPL equity shares from a few selling shareholders, for a total of 520,408 SSPL equity shares, or 51 percent of the company's paid-up share capital. As a result of the acquisition, Advanced Enzyme will be able to benefit from synergies with SSPL and expand its business-to-consumer categories. On 1st February 2021, Novozymes, a global pioneer in biological solutions, is expanding beyond its current foundation of microbial goods and innovation to enter the agricultural biocontrol area with promising enzyme-based technology. The new technology has the potential to control major pests that have a negative influence on agriculture and result in billions of dollars in annual losses. On 15th July 2021, Axtra PHY GOLD, the industry-leading new phytase enzyme, has been extended in Malaysia, Thailand, and Australia, according to Danisco Animal Nutrition, a branch of IFF's Health & Biosciences division. Axtra PHY GOLD was first marketed in India in 2020, and it will be available in all Asia Pacific markets after regulatory approval is received. Axtra PHY GOLD is the most bio effective phytase on the market today., allowing farmers to boost sustainability while reducing feed costs. Segments Covered in the Report By Product Buy this Premium Research Report@  https://www.precedenceresearch.com/checkout/1382 You can place an order or ask any questions, please feel free to contact at  sales@precedenceresearch.com  | +1 9197 992 333 About Us Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally. For Latest Update Follow Us:

Lesaffre Investments

1 Investments

Lesaffre has made 1 investments. Their latest investment was in Intralytix as part of their Corporate Minority on June 6, 2017.

CBI Logo

Lesaffre Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/12/2017

Corporate Minority

Intralytix

$17.5M

Yes

4

Date

6/12/2017

Round

Corporate Minority

Company

Intralytix

Amount

$17.5M

New?

Yes

Co-Investors

Sources

4

Lesaffre Portfolio Exits

1 Portfolio Exit

Lesaffre has 1 portfolio exit. Their latest portfolio exit was Envera on March 01, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/1/2021

Acq - Fin

3

Date

3/1/2021

Exit

Acq - Fin

Companies

Valuation

Acquirer

Sources

3

Lesaffre Acquisitions

9 Acquisitions

Lesaffre acquired 9 companies. Their latest acquisition was NattoPharma on May 24, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

5/24/2021

$991

Acquired

7

6/9/2020

Subscribe to see more

$99M

Subscribe to see more

10

11/26/2018

Corporate Majority

Subscribe to see more

$99M

Subscribe to see more

10

7/13/2018

Subscribe to see more

$99M

Subscribe to see more

10

11/20/2017

Corporate Majority

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/24/2021

6/9/2020

11/26/2018

7/13/2018

11/20/2017

Investment Stage

Corporate Majority

Corporate Majority

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

Total Funding

$99M

$99M

$99M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

7

10

10

10

10

Lesaffre Partners & Customers

1 Partners and customers

Lesaffre has 1 strategic partners and customers. Lesaffre recently partnered with Meiogenix on June 6, 2016.

Date

Type

Business Partner

Country

News Snippet

Sources

6/7/2016

Partner

Meiogenix

France

Meiogenix and Lesaffre Collaborate to Improve Industrial Yeast Strains’ Performance

Under the collaboration agreement Meiogenix will apply its non-GM technology to discover novel yeast strains with improved industrial properties that will be then industrialized by Lesaffre , a global key player in yeasts and fermentation .

2

Date

6/7/2016

Type

Partner

Business Partner

Meiogenix

Country

France

News Snippet

Meiogenix and Lesaffre Collaborate to Improve Industrial Yeast Strains’ Performance

Under the collaboration agreement Meiogenix will apply its non-GM technology to discover novel yeast strains with improved industrial properties that will be then industrialized by Lesaffre , a global key player in yeasts and fermentation .

Sources

2

Lesaffre Team

2 Team Members

Lesaffre has 2 team members, including former Chief Financial Officer, Philippe Guillaumie.

Name

Work History

Title

Status

Philippe Guillaumie

SEGULA Technologies

Chief Financial Officer

Former

Edward Antoszkiewicz

Groupe SEB, Lactalis, and Nestle

Chief Commercial Officer

Former

Name

Philippe Guillaumie

Edward Antoszkiewicz

Work History

SEGULA Technologies

Groupe SEB, Lactalis, and Nestle

Title

Chief Financial Officer

Chief Commercial Officer

Status

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.